Palladon (Hydromorphone Hydrochloride)

Hydromorphone hydrochloride is an opioid that acts on the central nervous system to relieve pain across several clinical contexts.

• Acute postoperative pain: provides rapid analgesia following surgical procedures.
• Cancer‑related pain: helps control persistent pain associated with malignant disease.
• Severe chronic non‑cancer pain: offers relief when other opioids or analgesics are inadequate.
• Pain from traumatic injury: reduces intense pain from fractures or major tissue damage.

• Hydromorphone binds selectively to μ‑opioid receptors in the central nervous system, mimicking endogenous opioid peptides. This binding inhibits the release of excitatory neurotransmitters, decreases neuronal excitability, and alters pain signal transmission, resulting in reduced perception of pain.

Hydromorphone may cause a range of adverse reactions, from mild to potentially life‑threatening.

Common Side Effects

• Nausea and vomiting
• Constipation
• Drowsiness or sedation
• Dizziness
• Dry mouth
• Sweating

Serious or Rare Side Effects

• Respiratory depression
• Severe hypotension
• Bradycardia
• Allergic reactions such as rash or anaphylaxis
• Confusion or delirium
• Urinary retention

When using hydromorphone, clinicians should consider several safety measures to minimize risk.

• Assess pain severity and prior opioid exposure: tailor dosing to individual needs.
• Monitor for signs of respiratory depression: especially during initiation and dose escalation.
• Evaluate renal and hepatic function: adjust use in impairment.
• Avoid concurrent use with other central nervous system depressants: increases sedation risk.
• Educate patients on proper storage and disposal: prevent accidental ingestion.
• Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Hydromorphone can interact with various medications, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Concomitant use with other strong opioid opioids: heightened risk of respiratory depression.
• Benzodiazepines or barbiturates: additive central nervous system depression.
• MAO inhibitors: may precipitate severe hypotension or serotonin syndrome.

Moderate Interactions (Monitor Closely)

• CYP3A4 inhibitors (e.g., ketoconazole): may increase hydromorphone plasma levels.
• CYP3A4 inducers (e.g., rifampicin) :  
• Anticholinergic agents: may worsen constipation.
• Antihistamines: may enhance sedation.
• Diuret‑t